PALVELLA THERAPEUTICS, INC.PVLAEarnings & Financial Report
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare, debilitating genetic diseases with high unmet medical needs. Its lead product candidates address congenital disorders, serving global patient populations that lack effective existing treatment options.
PVLA Q4 FY2025 Key Financial Metrics
Revenue
$520.0K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
14.3%
PALVELLA THERAPEUTICS, INC. Q4 FY2025 Financial Summary
PALVELLA THERAPEUTICS, INC. reported revenue of $520.0K (up 14.3% YoY) for Q4 FY2025, with a net profit of N/A (down 221.8% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $520.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
PALVELLA THERAPEUTICS, INC. Annual Revenue by Year
PALVELLA THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.6M).
PALVELLA THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
PALVELLA THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $520.0K | +14.3% | N/A | N/A |
| Q3 FY2025 | $628.0K | — | $-11.3M | -1806.5% |
| Q2 FY2025 | $690.0K | — | $-9.5M | -1372.6% |
| Q1 FY2025 | $752.0K | +1318.9% | $-8.2M | -1088.4% |
| Q3 FY2024 | $0 | — | $-6.8M | N/A |
| Q2 FY2024 | $0 | — | $-4.2M | N/A |
| Q1 FY2024 | $53.0K | -97.3% | $-2.5M | -4784.9% |
| Q4 FY2023 | $1.3M | -77.8% | N/A | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $53000 | $0 | $0 | $752000 | $690000 | $628000 | $520000 |
| YoY Growth | -77.8% | -97.3% | N/A | N/A | 1318.9% | N/A | N/A | 14.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.5M | $29.5M | $25.1M | $20.5M | $79.4M | $73.7M | $66.9M | $59.6M |
| Liabilities | $11.4M | $106.4M | $105.9M | $107.9M | $23.9M | $26.0M | $28.3M | $31.6M |
| Equity | $-74.5M | $-76.9M | $-80.8M | $-87.4M | $55.6M | $47.8M | $38.7M | $28.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-13.7M | $-1.1M | $-1.6M | $-2.7M | $-6.8M | $-5.4M | $-7.9M | $-25.0M |